FY2025 · ended Dec 31, 2025 · Revenue $99.99M, +25.1% YoY · Filed Mar 3, 2026
Neuropace, Inc. (NPCE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $100.0 million and a net loss of $21.5 million. Free cash flow was -$11.3 million. As of Jun 30, 2026 it held $51.7 million in cash and investments and $69.9 million in total debt.
Revenue (TTM)
$106.99M
+33.2% vs year-ago TTM
Net income (TTM)
$-19.11M
+26.3% vs year-ago TTM
Operating cash flow (TTM)
$-11.24M
+30.1% vs year-ago TTM
Free cash flow (TTM)
$-11.61M
+29.3% vs year-ago TTM
EPS (TTM)
$-0.57
+32.2% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
33.67M
+3.4% vs prior year
Net cash
$-18.23M
as of Jun 30, 2026
Operating margin
-11.3%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NPCE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1528287
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | -$36.1M |
| Diluted EPS | -$0.66 | -$0.93 | -$1.27 | -$1.91 | -$2.17 |
| Operating cash flow | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M |
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M |
| Stockholders' equity | $19.0M | $8.0M | $20.7M | $34.8M | $73.5M |
| Cash and investments | $61.1M | $52.8M | $66.5M | $77.4M | $115.6M |
| Total debt | $70.8M | $73.3M | $72.4M | $69.8M | $49.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | Mar 31, 2026 |
All 353 Neuropace, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.